Eversense Continuous Glucose Monitoring System
Senseonics, Incorporated · Decision date Mar 19, 2026
What did the FDA approve?
FDA records P160048/S031 as a supplement to PMA P160048, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 19, 2026.
FDA approval order statement
Approval of the revised protocol for the post-approval study (PAS) protocol.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Clinical Chemistry
- Decision date
- Mar 19, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P160048/S031
- Regulatory pathway
- PMA supplement
- Applicant
- Senseonics, Incorporated
- Product code
- QCD
- Decision code
- APPR
- Decision date
- Mar 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Continuous glucose monitor, implanted, adjunctive use.
- Applicant
- Senseonics, Incorporated
- Product code
- QCD
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160048/S031 received
Application receipt date recorded by FDA.
P160048/S031 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P160048. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Senseonics, Incorporated
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 20451 Seneca Meadows Pkwy., Germantown, MD, 20876
Sources and methodology
- Original FDA record: P160048/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records